

Charles Orsatti Elected to AngioDynamics' Board of Directors

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- October 24, 2008

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that at its annual meeting shareholders elected Charles Orsatti to the Board of Directors. Mr. Orsatti succeeds Robert Flaherty who decided to not pursue re-election to the Board. The size of the AngioDynamics Board of Directors remains unchanged, at nine members.

Mr. Orsatti brings a distinguished career to the AngioDynamics' Board. He has served in leadership positions with several healthcare and medical technology companies and currently serves on the Board of Directors of two other companies in the healthcare industry. During his 20 years in senior level positions in both public and private companies, Mr. Orsatti has served as Chairman and Chief Executive Officer of Fairfield Medical Products Corporation, Chief Operating Officer of Glasrock Home Health Care, President of Ohmeda Medical Engineering Division of British Oxygen Corporation, and Chief Executive Officer of Coloplast. In addition, Mr. Orsatti has served on the Board of Directors of dj Orthopedics, LLC and Vitagen, Inc. and currently serves on the Board of Directors of SRI Surgical, Inc. and Gyntec, Inc. He has also been Chairman and Managing Partner of J.P. Morgan Fairfield Partners, a private equity firm, and currently is Chairman and Managing Partner of Fairfield Partners, which is also a private equity firm. Mr. Orsatti earned a Bachelor of Science degree from Penn State University.

"Chuck has a long and successful career in maximizing returns for shareholders and brings valuable operational and oversight experience in the healthcare industry to AngioDynamics," said Eamonn Hobbs, President and Chief Executive Officer of AngioDynamics. "His current and previous Board experience, combined with his track record as an executive, will be a key asset to our company as we consistently explore ways to maximize shareholder value. We look forward to working with him, and, at the same time, thank Bob Flaherty for his many years of dedicated service and invaluable contributions to our company," concluded Mr. Hobbs.

In addition, the Company also reported today that shareholders elected all nominees for director and approved all proposals presented at its annual meeting.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation and irreversible electroporation resection systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms" "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to integrate the purchased Diomed businesses as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2008. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Source: AngioDynamics, Inc.